Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized control trial - Arabi, Y; Gordon, A; Derde, L; Nichol, A; Murthy, S; Al-Beidh, F; Annane, D; Al, Swaidan L; Beane, A; Beasley, R; Berry, L; Bhimani, Z; et al. (Intensive Care Medicine, 2021)